文献速递类风湿关节炎其他结缔组织病

DMARD类别与RA及RA-ILD患者ILD风险及安全性结局

Risk of ILD and safety outcomes across DMARD classes in rheumatoid arthritis and RA-ILD.
PubMed 文献 · Semin Arthritis Rheum · 2026-01-11

韩国全国队列研究纳入26,120例新诊断RA患者,比较TNFi、非TNFi生物制剂、JAKi与csDMARDs的ILD风险及安全性。调整后各DMARD类别ILD发生率相似;非TNFi生物制剂与住院、感染及死亡风险升高相关,尤其在RA-ILD患者中。

要点

  • 各DMARD类别间ILD发生率及ILD相关住院无显著差异。
  • 非TNFi生物制剂与住院、感染和死亡风险升高相关。
  • RA-ILD患者使用非TNFi生物制剂时肺炎相关住院和复发更多。

核心结论

  • DMARD类别与ILD发生率或ILD相关住院无显著关联。
  • 非TNFi生物制剂持续与肺炎相关住院、复发和死亡风险增加相关。

研究设计与样本

  • 韩国全国队列研究,使用国民健康保险服务数据(2011-2020),随访至2022年。
  • 纳入26,120例新诊断RA且至少使用一种csDMARD的成人,共209,852个治疗 episodes,其中RA-ILD患者641例(1688 episodes)。

主要发现

  • 调整后各DMARD类别ILD发生率相似。
  • 在RA和RA-ILD中,非TNFi生物制剂较csDMARDs与更高住院风险相关(RA aHR 1.30,95%CI 1.21-1.40;RA-ILD aHR 1.35,95%CI 1.02-1.80)。
  • 非TNFi生物制剂较csDMARDs与更高感染风险相关(RA aHR 1.16,95%CI 1.05-1.28;RA-ILD aHR 1.51,95%CI 1.06-2.15)。
  • 非TNFi生物制剂较csDMARDs与更高死亡风险相关(RA aHR 4.09,95%CI 3.04-5.50;RA-ILD aHR 4.31,95%CI 2.21-8.41)。
  • TNFi和JAKi与住院或感染无显著关联;MACE风险各组无差异。

关键数值与推荐

  • RA-ILD定义为≥2次ILD索赔加胸部CT确认。
  • 采用时间变化Cox模型和逆概率治疗加权进行首次事件分析。

临床怎么用

  • 使用非TNFi生物制剂的患者需密切监测感染,尤其RA-ILD患者。
  • DMARD类别选择对ILD发生率影响不显著,但需权衡非TNFi生物制剂的感染和死亡风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the risk of interstitial lung disease (ILD) and safety outcomes of disease-modifying antirheumatic drug (DMARD) classes in rheumatoid arthritis (RA), focusing on patients with RA-associated ILD (RA-ILD). METHODS: We conducted a nationwide cohort study using Korean National Health Insurance Service data (2011-2020). Adults with newly diagnosed RA prescribed at least one csDMARD were included and followed until 2022. Four treatment groups were evaluated: TNFi, non-TNFi biologics (abatacept, rituximab, tocilizumab), JAKi, and csDMARDs. RA-ILD was defined as ≥2 ILD claims plus chest computed tomography confirmation. Outcomes included ILD incidence, hospitalisation, infection, MACE, and all-cause mortality. Time-varying Cox models with inverse probability of treatment weighting were applied for first-event analyses. RESULTS: We analysed 26,120 patients with RA (209,852 treatment episodes), including 641 RA-ILD patients (1688 episodes). Adjusted ILD incidence was similar across DMARD classes. In RA and RA-ILD, non-TNFi biologics were associated with higher risks of hospitalisation (RA aHR 1.30, 95% CI 1.21-1.40; RA-ILD 1.35, 1.02-1.80), infection (RA 1.16, 1.05-1.28; RA-ILD 1.51, 1.06-2.15), and mortality (RA 4.09, 3.04-5.50; RA-ILD 4.31, 2.21-8.41) compared with csDMARDs. ILD-related admissions were similar, but pneumonia-related hospitalisations and recurrences were higher with non-TNFi biologics. TNFi and JAKi showed no significant associations with hospitalisation or infection. MACE risk did not differ across groups. CONCLUSIONS: DMARD class was not associated with ILD incidence or ILD-related hospitalisation. Non-TNFi biologics were consistently linked to increased pneumonia-related hospitalisation, recurrence, and mortality, highlighting the need for close infection monitoring in patients receiving these agents.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Lee KA, Lee B, Kim HS, et al. Risk of ILD and safety outcomes across DMARD classes in rheumatoid arthritis and RA-ILD. Semin Arthritis Rheum. 2026. PMID: 41534248. doi:10.1016/j.semarthrit.2026.152921

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。